Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Alexandra D Dreyfuss, P. Bravo, C. Koumenis, B. Ky
Published 2019 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Modern oncologic therapies and care have resulted in a growing population of cancer survivors with comorbid, chronic health conditions. As an example, many survivors have an increased risk of cardiovascular complications secondary to cardiotoxic systemic and radiation therapies. In response, the field of cardio-oncology has emerged as an integral component of oncologic patient care, committed to the early diagnosis and treatment of adverse cardiac events. However, as current clinical management of cancer therapy–related cardiovascular disease remains limited by a lack of phenotypic data, implementation of precision medicine approaches has become a focal point for deep phenotyping strategies. In particular, -omics approaches (a field of study in biology ending in -omic, such as genomics, proteomics, or metabolomics) have shown enormous potential in identifying sensitive biomarkers of cardiovascular disease, applying sophisticated, pattern-revealing technologies to growing databases of biologic molecules. Moreover, the use of -omics to inform radiologic strategies may add a dimension to future clinical practices. In this review, we present a paradigm for a precision medicine approach to the care of cardiotoxin-exposed cancer patients. We discuss the role of current imaging techniques; demonstrate how -omics can advance our understanding of disease phenotypes; and describe how molecular imaging can be integrated to personalize surveillance and therapeutics, ultimately reducing cardiovascular morbidity and mortality in cancer patients and survivors.
This paper references
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children
H. Visscher (2013)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
J. Zamorano (2016)
Novel Approach to Early Detection of Doxorubicin Cardiotoxicity by Gadolinium-Enhanced Cardiovascular Magnetic Resonance Imaging in an Experimental Model
James C. Lightfoot (2010)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
D. Cardinale (2010)
The incidence and functional consequences of RT-associated cardiac perfusion defects.
L. Marks (2005)
Cardiovascular Magnetic Resonance in the Oncology Patient
J. Jordan (2018)
Emerging Role of Precision Medicine in Cardiovascular Disease.
J. Leopold (2018)
Negative correlation between coronary flow reserve and mean radiation dose to the heart [abstract
JD Groarke (2014)
N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?
M. Sandri (2005)
Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy
K. Leger (2017)
Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution.
P. Lind (2003)
Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy
JD Evans (2013)
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
H. Visscher (2012)
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Sasha E Stanton (2015)
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
C. Yancy (2013)
Proteomic insights into chronic anthracycline cardiotoxicity.
M. Štěrba (2011)
A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.
H. Stary (1992)
Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography.
V. Mor-Avi (2011)
Identification of a novel microRNA profile in pediatric cancer patients treated with anthracycline chemotherapy
KE Oatmen (2018)
Using DNA. Radiation therapy
E Dolgin (2016)
Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy.
Kelsie E. Oatmen (2018)
Negative Correlation Between Coronary Flow Reserve and Mean Radiation Dose to the Heart
J. Groarke (2014)
Assessment of late anthracycline-induced cardiotoxicity by 123I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence
M. D. Santos (2015)
The Role of Cardiac PET in Translating Basic Science into the Clinical Arena
P. Bravo (2011)
A toxicoproteomic study on cardioprotective effects of pre-administration of docetaxel in a mouse model of adriamycin-induced cardiotoxicity.
K. Ohyama (2010)
Symptomatic cardiac events following radiation therapy for left-sided breast cancer: possible association with radiation therapy-induced changes in regional perfusion.
X. Yu (2003)
Using DNA, radiation therapy gets personal.
Elie Dolgin (2016)
Ideal cardiovascular health metrics and risk of cardiovascular disease or mortality: A meta-analysis.
N. Fang (2016)
When Left Ventricular Extracellular Volume Fraction Changes After Anthracyclines: Is it Due to a Change in the Numerator, Denominator, or Both?
W. Hundley (2018)
Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
Lynn A. Beer (2016)
PET/MRI of inflammation in myocardial infarction.
Won Woo Lee (2012)
Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results.
P. Hardenbergh (2001)
Cancer treatment and survivorship statistics, 2016
K. Miller (2016)
Cardiac Sympathetic Hyperactivity after Chemotherapy: Early Sign of Cardiotoxicity?
Sarita Lígia Pessoa de Melo Machado Guimarães (2015)
Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.
S. Galper (2011)
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Brandon C. Drafts (2013)
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
J. Blanco (2012)
Cancer treatment and survivorship statistics
K D Miller (2016)
Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography.
E. Folco (2011)
Longitudinal Assessment of Concurrent Changes in Left Ventricular Ejection Fraction and Left Ventricular Myocardial Tissue Characteristics After Administration of Cardiotoxic Chemotherapies Using T1-Weighted and T2-Weighted Cardiovascular Magnetic Resonance
J. Jordan (2014)
Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer.
Brian S. Finkelman (2017)
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
J. Plana (2014)
Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.
B. Ky (2014)
Genetic susceptibility to anthracycline‐related congestive heart failure in survivors of haematopoietic cell transplantation
S. Armenian (2013)
Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity.
K. Negishi (2013)
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Edward H. Romond (2012)
Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis.
B. Kietselaer (2004)
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
D. Cardinale (2004)
Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
P. Thavendiranathan (2013)
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease.
T. Tang (2009)
In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents
N. Boutagy (2018)
Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults
Quinn S. Wells (2017)
Detection of Dose Response in Chronic Doxorubicin-Mediated Cell Death with Cardiac Technetium 99m Annexin V Single-Photon Emission Computed Tomography
K. Gabrielson (2008)
Detection of Myocardial Metabolic Abnormalities by 18F-FDG PET/CT and Corresponding Pathological Changes in Beagles with Local Heart Irradiation
R. Yan (2015)
Radiation therapy gets personal
E Dolgin (2016)
Annexin V single-photon emission computed tomography
Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
H. Narayan (2016)
This paper is referenced by
Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy
Rafey A. Feroze (2020)
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.
W. Weber (2020)
Cardio-Oncology Preventive Care: Racial and Ethnic Disparities
P. Prasad (2020)
Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
Sherry-Ann Brown (2020)
The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine
Rudolf A. Werner (2020)
Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools.
L. Pang (2020)
Evolving Role of Novel Quantitative PET Techniques to Detect Radiation-Induced Complications.
Alexandra D Dreyfuss (2020)
Emerging Challenges of Radiation-Associated Cardiovascular Dysfunction (RACVD) in Modern Radiation Oncology: Clinical Practice, Bench Investigation, and Multidisciplinary Care
Moon-Sing Lee (2020)
The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology
Olubadewa A. Fatunde (2020)
Cardiovascular care of the oncology patient during COVID-19: An expert consensus document from the ACC Cardio-Oncology and Imaging Councils
Lauren A Baldassarre (2020)